XtalPi (“QuantumPharm Inc.”, stock code: 2228.HK) is a quantum physics-based, AI-powered drug R&D company dedicated to revolutionizing drug discovery and development by significantly improving the speed, scale and success rate of therapeutic innovations. With operations in both China and the U.S., we leverage advanced capabilities and resources in each market to meet the diverse needs of our customers and collaborators across the pharmaceutical and biotechnology industries.

Our cutting-edge cloud integrated platform is meticulously designed to optimize quantum physics based algorithms, in silico modeling, and computational chemistry using experimental data generated from our state-of-the-art automated wet lab. This approach enhances the efficiency and productivity of laboratory workflows, allowing for accelerated candidate selection and lead optimization in small molecule discovery, along with robust crystal structure prediction and polymorph screening in solid state chemistry. We are strategically positioned at the forefront of a transformative shift in pharmaceuticals, where the convergence of AI, computational chemistry and automation is increasingly critical for the success of novel therapeutics and targeted therapies.